Teva UK and Closed Loop Medicine partner to bolster personalized medicines
Under the agreement, Teva UK will investigate opportunities to use Closed Loop Medicine’s proprietary software as a medical device (SaMD) technology platform which aims to advance the development of personalized medicines with specific chronic disorders by combining dose-optimised drug therapy with digital care.
Dr Paul Goldsmith, chief medical officer and innovation officer, co-founder and president of Closed Loop Medicine, said: “As clinicians, we know that dosing of drugs is a huge problem. In the most extreme cases, we are seeing patients having severe adverse events, for example when required to change dose levels to undergo surgery. Being able to predict personalized dose levels could be transformational.”
This tie-up aims to create the opportunity for digital companions to be prescribed alongside traditional therapeutics, enabling real-world data integration.
Recent clinical trial results for a hypertension product, CLM-HT01, have demonstrated the technology’s ability to dose optimise drug therapy and minimise side effects whilst achieving blood pressure control, with ‘exceptionally high’ medication adherence.
Personalized medicine is an aspiration of the modern healthcare system, yet existing medicines are typically prescribed based on their average effects in a population and rarely dose optimised for the individual.
This “one size fits all” approach can result in increased side effects and adverse reactions, poor patient outcomes and high costs.
For example, the annual cost of drug-related morbidity and mortality resulting from non-optimised medication was estimated at $528.4 billion in the US in 2016 and £2.21 billion in the UK NHS.
Kim Innes, Teva’s general manager, UK & Ireland, commented: “We are excited to be working with Closed Loop Medicine, who have demonstrated themselves to be compelling innovators in the area of personalized medicine.
“We know that the patient experience can sometimes be less than optimal and as the largest supplier of medicines to the NHS, the potential to combine ‘drug’ & ‘digital’ could create significant improvements to lives of patients at great scale. We are very excited about the future of this partnership.”
The integration of real-world data can enable personalisation of dosing that has not been available before, added Dr. Hakim Yadi, CEO and co-founder of Closed Loop Medicine.
“This commercial partnership is an example of the potential and scalability of our SaMD technology platform, demonstrating the value that can be added by integrating software to well-known and trusted brands to improve disease management and patient outcomes at an individual level,” he said.
